Overview

We have a strong track record of collaboration with global partners. Such collaboration serves two distinct purposes. The first is to in-license innovative clinical assets with first-in-class and best-in-class potential. Through in-licensing efforts with reputable global pharma or biotech partners, including MorphoSys, Genexine and Ferring, we have built up our China Portfolio to enhance our competitiveness while balancing the development risk of our pipeline. In that respect, we are often considered an ideal China partner by our global counterparts because of our strong development capabilities and track record.

For all of our in-licensed clinical assets, we have demonstrated our capability to rapidly build IND-enabling data packages to facilitate regulatory approvals and quickly advance clinical development of the assets. For TJ301, TJ202 and TJ107, we have successfully completed IND applications with robust data packages to start Phase 2 and Phase 3 clinical trials in China, with TJ301 commencing a Phase 2 clinical trial already. These achievements have impressed our existing partners and triggered discussions on additional in-licensing opportunities; they have also helped our negotiations with new global partners. Our effort to identify and selectively in-license innovative medicines for unmet medical needs in China will continue. Our China Portfolio strategy is made feasible by recent NMPA regulatory policy reforms, which significantly clarifies and facilitates the review and approval processes for innovative drugs in China.

The second aspect of our partnerships is related to out-licensing or co-development of the high-value assets in our pipeline as part of our global development strategy. By leveraging external resources and strength, we seek either out-licensing or partnering opportunities with other companies to capture the full value of our assets.

We have begun to build a meaningful revenue stream through these out-licensing or co-development deals in advance of the product sales revenues we expect to realize starting in 2021.

Partners

Partnering Opportunities

At I-Mab, we strive to develop innovative therapies that have the potential to become first-in-class and best-in-class medicines.

Currently, we are seeking strategic partners in the following areas:

In-licensing highly differentiated large molecules in immuno-oncology and autoimmune disease.
Co-development and co-commercialization of our innovative products for the global market.

BD Contacts:

If you are interested in exploring business opportunities with us, please send your request to: BD@i-mabbiopharma.com
Copyright I-Mab Biopharma (Shanghai) Co., Ltd. all rights reserved 2017沪ICP备17007960号-1